Giant cell arteritis (GCA) Market Insights, Epidemiology and Market Forecast-2028

OsteoporosisMarket Insights, Epidemiology and Market Forecast2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Osteoporosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Osteoporosis from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 20172028

Osteoporosis - Disease Understanding and Treatment Algorithm

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis is a bone disorder that increases a persons risk of fracture due to low bone mineral density (BMD), impaired bone microarchitecture/mineralization, and/or decreased bone strength. Although osteoporosis is typically associated with women, it is also diagnosed in men, who account for an estimated one in five Americans who have osteoporosis or low bone mineral density (BMD). In addition to being the major cause of fractures in the older population, osteoporosis is also highly associated with people becoming bedridden, which can lead to serious complications. Osteoporosis can be divided into primary and secondary osteoporosis, wherein primary occurs with age and sex hormone deficiency and secondary osteoporosis occurs with several comorbid diseases and medications.
Osteoporosis can be diagnosed with a BMD test, bone mineral density (BMD) test, Fracture Risk Assessment Tool Model (FRAX), Vertebral imaging (Vertebral fracture assessment), Biochemical bone turnover marker (BTM), Quantitative Ultrasound (QUS), Quantitative Computed Tomography (QCT) and Peripheral QCT (pQCT) and Quality of DXA AND VFA. BMD tests can identify osteoporosis, determine the risk for fractures (broken bones), and measure response to osteoporosis treatment. The most widely recognized BMD test is a central dual-energy x-ray absorptiometry or central DXA test. Treatment of osteoporosis is strictly related to the severity of pathology. Initially, it is important to prevent fragility fractures with an active lifestyle and adequate nutritional supplements, including daily calcium and vitamin D intake, performing weight-bearing activities, avoiding or stopping smoking, and avoiding heavy alcohol consumption.
The DelveInsight Osteoporosis market report gives the thorough understanding of Osteoporosis by including details such as disease introduction, types of osteoporosis, causes of osteoporosis, symptoms, pathophysiology, pathology, risk factors, diagnosis, diagnostic biomarkers and differential diagnosis.
Osteoporosis Epidemiology
According to the International Osteoporosis Foundation (IOF), around the world, one in three women and one in five men aged fifty years and over are at risk of an osteoporotic fracture. In fact, an osteoporotic fracture is estimated to occur every 3 s. The most common fractures associated with osteoporosis occur at the hip, spine, and wrist. The likelihood of these fractures occurring, particularly at the hip and spine, increases with age in both women and men. IOF estimate that over 44 million people in the United States currently have osteoporosis. Approximately 30% of all postmenopausal women have osteoporosis in the United States and Europe. At least 40% of these women and 1530% of men will sustain one or more fragility fractures in their remaining lifetime. An increased risk of 86% for any fracture has been demonstrated in people that have already sustained a fracture. Likewise, patients with a history of vertebral fracture have a 2.3-fold increased risk of future hip fracture and a 1.4-fold increase in the risk of distal forearm fracture.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Osteoporosis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 20172028 for the following aspects:
The disease epidemiology covered in the report is segmented by:
Prevalence of Osteoporosis
Diagnosed Prevalent Population of Osteoporosis
Gender-specific Prevalence of Osteoporosis
Prevalence of Primary Osteoporosis
Prevalence of Secondary Osteoporosis
Incidence of Osteoporotic Fractures
Osteoporosis-related comorbidities

As per a study conducted by Rausch et al. titled We miss the opportunity: Pretreatment of osteoporosis in a German trauma center, in Germany, the prevalence for osteoporosis in individuals of age 50 and above is estimated to be around 26% overall and 39% in women. In males, prevalence is estimated to be on a significantly lower level with 9.7% of the population over 50 years. Approximately 399 patients >60 years suffering low-energy-fractures of their spine, femur, humerus or forearm between 2014 and 2015 were recruited in a German trauma center. In about 21% (84 out of 399) of all patients, osteoporosis was diagnosed prior to current admission. Nearly 34% (136 out of 399) suffered a prior risk-fracture after age of 50. Also, 38% (19 out of 50) of these patients with fragility fractures and prior osteoporosis diagnosis received anti-osteoporotic medication. In case of corticoids taken by the patients, about 15.4% and 13.3% resulted in osteoporosis with prior and no prior fracture, respectively.
A clinical review study by the US Preventive Services Task Force Recommendation Statement projected that by 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis. Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 2130% of patients who experience a hip fracture die within 1 year.

Osteoporosis Drug Chapters

This segment of the Osteoporosis report encloses the detailed analysis of the drugs that are expected to be launched in other regions. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Osteoporosis and awareness of the disease. The overall dynamics of Osteoporosis market is anticipated to change in the coming years owing to the expected launch of emerging therapies that are already approved in specific regions but are expected to be launched in other regions as well. The major key players such as Amgen, Radius Health, and others will significantly increase the market during the forecast period (20192028).

Osteoporosis Market Outlook

Osteoporosis is a metabolic bone disease characterized by an imbalance between bone resorption and accrual, resulting in microarchitectural disruption, reduced bone mineral density (BMD), and skeletal fragility. Fragility fractures are common in the osteoporotic population and occur from forces, not ordinarily resulting in fracture. The most common sites are the vertebral column, hip and wrist; however, fragility fractures of the humerus, pelvis and ribs are not uncommon.
The treatment for Osteoporosis majorly includes pharmacological therapies to reduce the risk of fractures. Medications to treat osteoporosis are categorized as either antiresorptive (i.e., bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab) or anabolic (i.e., teriparatide). Bisphosphonates are therefore effective agents to increase bone mineral density (BMD) at the spine and hip when used as primary prevention or as treatment in both men and women on long-term glucocorticoids.
The treatment of Osteoporosis mainly follows a mainstay treatment, i.e., pharmacological agents (bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, calcitonin, the 134 fragment of parathyroid hormone), calcium and vitamin D supplements, and calcitriol followed by surgery which is only preferred in case of severe osteoporosis cases in patients.
This segment gives a through detail of market trend of each therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Osteoporosis in the 7MM is expected to change from 20192028.

Osteoporosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 20172028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Approval of therapies for Osteoporosis such as Evenity (Amgen; to be launched in Europe), Tymlos (Radius Health; to be launched in Europe), and other targeted therapies in the forecast period [20192028] will also create a positive impact on the Osteoporosis market.

Osteoporosis Report Insights

Patient Population
Therapeutic Approaches
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Osteoporosis Report Key Strengths

10-Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition

Osteoporosis Report Assessment

Current Treatment Practices
Unmet Needs
Market Attractiveness
Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Osteoporosis market
Organize sales and marketing efforts by identifying the best opportunities for Osteoporosis market
To understand the future market competition in the Osteoporosis market.

Note: We understand the needs of the rapidly changing market and DelveInsights is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report.

List Of Tables

Table 1: WHO definitions of osteoporosis based on BMD
Table 2: Differential Diagnosis
Table 3: Total Diagnosed Prevalent Population of Osteoporosis in the 7MM Countries (20172028)
Table 4: Osteoporosis Prevalence in the United States (20172028)
Table 5: Osteoporosis Diagnosed Prevalent Population in the United States (20172028)
Table 6: Osteoporosis Gender-specific Prevalence in the United States (20172028)
Table 7: Primary Osteoporosis Prevalence in the United States (20172028)
Table 8: Secondary Osteoporosis Prevalence in the United States (20172028)
Table 9: Osteoporotic Fractures Incidence in the United States (20172028)
Table 10: Osteoporosis-related comorbidities in the United States (20172028)
Table 11: Osteoporosis Prevalence in Germany (20172028)
Table 12: Osteoporosis Diagnosed Prevalent Population in Germany (20172028)
Table 13: Osteoporosis Gender-specific Prevalence in Germany (20172028)
Table 14: Primary Osteoporosis Prevalence in Germany (20172028)
Table 15: Secondary Osteoporosis Prevalence in Germany (20172028)
Table 16: Osteoporotic Fractures Incidence in Germany (20172028)
Table 17: Osteoporosis-related comorbidities in Germany (20172028)
Table 18: Osteoporosis Prevalence in France (20172028)
Table 19: Osteoporosis Diagnosed Prevalent Population in France (20172028)
Table 20: Osteoporosis Gender-specific Prevalence in France (20172028)
Table 21: Primary Osteoporosis Prevalence in France (20172028)
Table 22: Secondary Osteoporosis Prevalence in France (20172028)
Table 23: Osteoporotic Fractures Incidence in France (20172028)
Table 24: Osteoporosis-related comorbidities in France (20172028)
Table 25: Osteoporosis Prevalence in Italy (20172028)
Table 26: Osteoporosis Diagnosed Prevalent Population in Italy (20172028)
Table 27: Osteoporosis Gender-specific Prevalence in Italy (20172028)
Table 28: Primary Osteoporosis Prevalence in Italy (20172028)
Table 29: Secondary Osteoporosis Prevalence in Italy (20172028)
Table 30: Osteoporotic Fractures Incidence in Italy (20172028)
Table 31: Osteoporosis-related comorbidities in Italy (20172028)
Table 32: Osteoporosis Prevalence in Spain (20172028)
Table 33: Osteoporosis Diagnosed Prevalent Population in Spain (20172028)
Table 34: Osteoporosis Gender-specific Prevalence in Spain (20172028)
Table 35: Primary Osteoporosis Prevalence in Spain (20172028)
Table 36: Secondary Osteoporosis Prevalence in Spain (20172028)
Table 37: Osteoporotic Fractures Incidence in Spain (20172028)
Table 38: Osteoporosis-related comorbidities in Spain (20172028)
Table 39: Osteoporosis Prevalence in the United Kingdom (20172028)
Table 40: Osteoporosis Diagnosed Prevalent Population in the United Kingdom (20172028)
Table 41: Osteoporosis Gender-specific Prevalence in the United Kingdom (20172028)
Table 42: Primary Osteoporosis Prevalence in the United Kingdom (20172028)
Table 43: Secondary Osteoporosis Prevalence in the United Kingdom (20172028)
Table 44: Osteoporotic Fractures Incidence in the United Kingdom (20172028)
Table 45: Osteoporosis-related comorbidities in the United Kingdom (20172028)
Table 46: Osteoporosis Prevalence in Japan (20172028)
Table 47: Osteoporosis Diagnosed Prevalent Population in Japan (20172028)
Table 48: Osteoporosis Gender-specific Prevalence in Japan (20172028)
Table 49: Primary Osteoporosis Prevalence in Japan (20172028)
Table 50: Secondary Osteoporosis Prevalence in Japan (20172028)
Table 51: Osteoporotic Fractures Incidence in Japan (20172028)
Table 52: Osteoporosis-related comorbidities in Japan (20172028)
Table 53: Comparison of Marketed Drugs
Table 54: Comparison of Emerging Drugs
Table 55: Alendronate/Zoledronic Acid, Clinical Trial Description
Table 56: NaQuinate, Clinical Trial Description
Table 57: 7 Major Market Size of Osteoporosis in USD Million (20172028)
Table 58: United States Market Size of Osteoporosis, USD Million (20172028)
Table 59: Market size of Osteoporosis by therapies in the United States, in USD Million (20172028)
Table 60: Market Size of Osteoporosis in Germany, in USD Million (20172028)
Table 61: Market size of Osteoporosis by therapies in Germany, in USD Million (20172028)
Table 62: Market Size of Osteoporosis in France, in USD Million (20172028)
Table 63: Market size of Osteoporosis by therapies in France, in USD Million (20172028)
Table 64: Market Size of Osteoporosis in Italy, in USD Million (20172028)
Table 65: Market size of Osteoporosis by therapies in Italy, in USD Million (20172028)
Table 66: Market Size of Osteoporosis in Spain, in USD Million (20172028)
Table 67: Market size of Osteoporosis by therapies in Spain, in USD Million (20172028)
Table 68: Market Size of Osteoporosis in the UK, in USD Million (20172028)
Table 69: Market size of Osteoporosis by therapies in the United Kingdom, in USD Million (20172028)
Table 70: Market Size of Osteoporosis in Japan, in USD Million (20172028)
Table 71: Market size of Osteoporosis by therapies in Japan, in USD Million (20172028)

List Of Figures

Figure 1: Normal bone vs. osteoporotic bone
Figure 2: Overview of the mechanisms of glucocorticoid-induced osteoporosis (GCOP).
Figure 3: Causes of osteoporosis
Figure 4: Symptoms of osteoporosis
Figure 5: Normal bone showing good connectivity as compared to osteoporotic bone showing poor conductivity.
Figure 6: Basic types of stresses that the bone endures
Figure 7: The pathogenesis of osteoporosis-related fractures
Figure 8: The bone remodeling cycle.
Figure 9: Suggested role of FRAX in the assessment of fracture risk
Figure 10: Circulating miRNAs differentially expressed in osteoporotic patients, either upregulated (roman) or downregulated (italic), and their functions studied in bone cells.
Figure 11: Suggested algorithm for diagnosis and management of postmenopausal osteoporosis.
Figure 12: Total Diagnosed Prevalent Patient Population of Osteoporosis in the 7MM Countries (20172028)
Figure 13: Osteoporosis Prevalence in the United States (20172028)
Figure 14: Osteoporosis Diagnosed Prevalent Population in the United States (20172028)
Figure 15: Osteoporosis Gender-specific Prevalence in the United States (20172028)
Figure 16: Primary Osteoporosis Prevalence in the United States (20172028)
Figure 17: Secondary Osteoporosis Prevalence in the United States (20172028)
Figure 18: Osteoporotic Fractures Incidence in the United States (20172028)
Figure 19: Osteoporosis-related comorbidities in the United States (20172028)
Figure 20: Osteoporosis Prevalence in Germany (20172028)
Figure 21: Osteoporosis Diagnosed Prevalent Population in Germany (20172028)
Figure 22: Osteoporosis Gender-specific Prevalence in Germany (20172028)
Figure 23: Primary Osteoporosis Prevalence in Germany (20172028)
Figure 24: Secondary Osteoporosis Prevalence in Germany (20172028)
Figure 25: Osteoporotic Fractures Incidence in Germany (20172028)
Figure 26: Osteoporosis-related comorbidities in Germany (20172028)
Figure 27: Osteoporosis Prevalence in France (20172028)
Figure 28: Osteoporosis Diagnosed Prevalent Population in France (20172028)
Figure 29: Osteoporosis Gender-specific Prevalence in France (20172028)
Figure 30: Primary Osteoporosis Prevalence in France (20172028)
Figure 31: Secondary Osteoporosis Prevalence in France (20172028)
Figure 32: Osteoporotic Fractures Incidence in France (20172028)
Figure 33: Osteoporosis-related comorbidities in France (20172028)
Figure 34: Osteoporosis Prevalence in Italy (20172028)
Figure 35: Osteoporosis Diagnosed Prevalent Population in Italy (20172028)
Figure 36: Osteoporosis Gender-specific Prevalence in Italy (20172028)
Figure 37: Primary Osteoporosis Prevalence in Italy (20172028)
Figure 38: Secondary Osteoporosis Prevalence in Italy (20172028)
Figure 39: Osteoporotic Fractures Incidence in Italy (20172028)
Figure 40: Osteoporosis-related comorbidities in Italy (20172028)
Figure 41: Osteoporosis Prevalence in Spain (20172028)
Figure 42: Osteoporosis Diagnosed Prevalent Population in Spain (20172028)
Figure 43: Osteoporosis Gender-specific Prevalence in Spain (20172028)
Figure 44: Primary Osteoporosis Prevalence in Spain (20172028)
Figure 45: Secondary Osteoporosis Prevalence in Spain (20172028)
Figure 46: Osteoporotic Fractures Incidence in Spain (20172028)
Figure 47: Osteoporosis-related comorbidities in Spain (20172028)
Figure 48: Osteoporosis Prevalence in the United Kingdom (20172028)
Figure 49: Osteoporosis Diagnosed Prevalent Population in the United Kingdom (20172028)
Figure 50: Osteoporosis Gender-specific Prevalence in the United Kingdom (20172028)
Figure 51: Primary Osteoporosis Prevalence in the United Kingdom (20172028)
Figure 52: Secondary Osteoporosis Prevalence in the United Kingdom (20172028)
Figure 53: Osteoporotic Fractures Incidence in the United Kingdom (20172028)
Figure 54: Osteoporosis-related comorbidities in the United Kingdom (20172028)
Figure 55: Osteoporosis Prevalence in Japan (20172028)
Figure 56: Osteoporosis Diagnosed Prevalent Population in Japan (20172028)
Figure 57: Osteoporosis Gender-specific Prevalence in Japan (20172028)
Figure 58: Primary Osteoporosis Prevalence in Japan (20172028)
Figure 59: Secondary Osteoporosis Prevalence in Japan (20172028)
Figure 60: Osteoporotic Fractures Incidence in Japan (20172028)
Figure 61: Osteoporosis-related comorbidities in Japan (20172028)
Figure 62: Treatment Algorithm for Osteoporosis
Figure 63: Treatment algorithm modified from Scottish Intercollegiate Guidelines Network, 2015
Figure 64: Algorithm for monitoring of long-term bisphosphonate therapy in postmenopausal women.
Figure 65: Unmet Needs of osteoporosis
Figure 66: 7 Major Market Size of Osteoporosis in USD Million (20172028)
Figure 67: Market Size of Osteoporosis in the United States, USD Millions (20172028)
Figure 68: Market size of Osteoporosis by therapies in the US, in USD Million (20172028)
Figure 69: Market Size of Osteoporosis in Germany, USD Million (20172028)
Figure 70: Market Size of Osteoporosis by therapies, in Germany, in USD Million (20172028)
Figure 71: Market Size of Osteoporosis in France, USD Million (20172028)
Figure 72: Market Size of Osteoporosis by therapies, in France, in USD Million (20172028)
Figure 73: Market Size of Osteoporosis in Italy, USD Million (20172028)
Figure 74: Market Size of Osteoporosis by therapies, in Italy, in USD Million (20172028)
Figure 75: Market Size of Osteoporosis in Spain, USD Million (20172028)
Figure 76: Market Size of Osteoporosis by therapies in Spain, in USD Million (20172028)
Figure 77: Market Size of Osteoporosis in the UK, USD Million (20172028)
Figure 78: Market Size of Osteoporosis by therapies in the UK, in USD Million (20172028)
Figure 79: Market Size of Osteoporosis in Japan, USD Million (20172028)
Figure 80: Market Size of Osteoporosis by therapies in Japan, in USD Million (20172028)
Figure 81: Market Drivers
Figure 82: Market Barriers

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available